Is there a role for neurotrophin treatment of the ocular surface following laser in situ keratomileusis (LASIK)?
Pepose
Jay S
JS
Johnson
Eugene M
EM
D003316:Corneal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D015352:Dry Eye Syndromes / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D005136:Eye Proteins / Q000378:metabolism; D006801:Humans; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects*; D054018:Lasers, Excimer; D009414:Nerve Growth Factors / Q000378:metabolism / Q000627:therapeutic use*; D018903:Photorefractive Keratectomy / Q000009:adverse effects; D013666:Tears / Q000378:metabolism
D005136:Eye Proteins; D009414:Nerve Growth Factors; C042434:tear proteins